SEC Form 4 · accession 0001209191-18-056987
Sarepta Therapeutics, Inc. · SRPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Hans Lennart Rudolf Wigzell
Director
Period of report
Nov 1, 2018
Accepted (ET)
Nov 2, 2018 · 6:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000873303
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 1, 2018 | M | 6,667 | $8.94 | A | 16,751 | D | |
| Common StockF1 | Nov 1, 2018 | S | 6,667 | $140.50 | D | 10,084 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $8.94 | Nov 1, 2018 | M | 6,667 | D | — | Feb 8, 2020 | Common Stock | 6,667 | 0 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $140.50 to $140.53, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with the range set forth herein.
- F2The option to purchase shares is fully vested.